For years the question about treatment in China was whether the quality was there at all. In obesity medicine that question has quietly been answered, because China's own drug candidates are now reporting Phase III numbers that belong in the same conversation as the drugs already prescribed in the United States and Europe. The interesting part is no longer whether they work. It is how the numbers compare, how well they are tolerated, and what happens next.
1. The Phase III Data
The most recent results arrived at EASD 2026, the 62nd annual meeting of the European Association for the Study of Diabetes, held in Milan and closing in early October.
BGM0504, a GLP-1/GIP dual agonist from BrightGene, was presented as a late-breaking abstract. The trial enrolled 652 overweight or obese Chinese adults in a multicentre, randomised, double-blind, placebo-controlled design, and ran for 52 weeks:
| Dose | Mean weight loss at 52 weeks |
|---|---|
| 5mg | 14.3% |
| 10mg | 17.3% |
| 15mg | 19.2% |
| Placebo | 3.1% |
Responder rates were high: 94.6% of the 15mg group lost at least 5% of body weight, 67.3% lost at least 15%, and 48.9% lost at least 20%. Waist circumference fell 16.5cm in the 15mg group against 3.3cm for placebo, and the trial also reported reductions in systolic blood pressure (12.8mmHg), uric acid (70.7μmol/L), triglycerides, HbA1c, fasting glucose and insulin. China's drug evaluation centre accepted the NDA in June 2026, so it is under review rather than available.
At the same meeting, Hansoh Pharma reported Phase III data for olatorepatid, a GLP-1/GIP dual agonist, showing 19.3% weight loss at week 48.
2. How That Compares
The most relevant reference point is tirzepatide, whose pivotal Phase III trial SURMOUNT-1 enrolled 2,539 adults over 72 weeks and reported mean weight loss of 16% at 5mg, 21.4% at 10mg and 22.5% at 15mg, against 2.4% for placebo.
Laid side by side:
| Weight loss | Trial duration | Participants | |
|---|---|---|---|
| Tirzepatide 15mg (SURMOUNT-1) | 22.5% | 72 weeks | 2,539 |
| BGM0504 15mg (Phase III) | 19.2% | 52 weeks | 652 |
| Olatorepatid (Phase III) | 19.3% | 48 weeks | — |
This is not a head-to-head comparison, and it should not be read as one. The trials differ in population, duration and design. Longer trials generally show greater cumulative loss, so the 52-week and 48-week figures are not measuring the same point on the curve as a 72-week figure. BGM0504's investigators made the same caution explicit in their own presentation, noting that cross-trial comparisons should be made carefully. Dividing 19.2 by 22.5 to produce a "percentage of equivalence" would be a misuse of the data.
What the table does support is a narrower and still significant claim: Chinese Phase III candidates are reporting weight loss in the same broad range as the leading approved drug, in trials of comparable rigour. Establishing anything stronger requires a head-to-head trial, which nobody has run. For reference, head-to-head data in this class does exist elsewhere: a direct comparison of tirzepatide with semaglutide found roughly 50% greater weight loss with tirzepatide. That is what a real comparison looks like, and it is why the absence of one here matters.
3. Tolerability, Where the Comparison Is Fairer
Weight-loss percentages are the headline, but they are also the least comparable number across trials, because they depend on dose, duration and how strictly patients adhered. Tolerability data is more directly comparable, because trials report it consistently.
Across the GLP-1 class the dominant side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, all generally transient and worst during dose escalation. In the BGM0504 trial, discontinuation because of adverse events was 0.7% to 1.7% across the three dose groups, with reactions described as mild-to-moderate and no new safety signals identified. That is the kind of figure a patient can actually weigh, and it sits in the same range reported for the approved drugs in this class.
Two practical points follow. First, titration matters more than the headline number: most tolerability problems are managed by escalating the dose more slowly, not by switching drugs. Second, these medicines are not a course you complete. Stopping usually means regaining the weight, so the relevant question for anyone considering treatment abroad is not just the first month, but the twelfth.
4. The Drug China Approved First
Mazdutide, from Innovent Biologics and sold in China as 信尔美, was approved by the NMPA on 27 June 2025 for long-term weight management. Chinese industry coverage describes it as the first GCG/GLP-1 dual receptor agonist approved for that indication anywhere.
The mechanism is the interesting part. Semaglutide acts on GLP-1; tirzepatide acts on GLP-1 and GIP; mazdutide acts on GLP-1 and GCG, the glucagon receptor. The rationale is that GLP-1 activity suppresses appetite while GCG activity increases energy expenditure, addressing both sides of the energy balance. That is a design rationale, not a demonstrated clinical advantage, and no head-to-head trial against tirzepatide has been reported. Approval tells you it cleared the regulatory bar, not that it is better than what came before.
5. What Is Available Now
As of October 2026, the drugs a patient in China can actually be prescribed for weight management include mazdutide, semaglutide (诺和盈) and tirzepatide (穆峰达). BGM0504 and olatorepatid are not yet approved.
The pipeline behind them is unusually crowded. Semaglutide's core patent in China expires on 20 March 2026, and around ten domestic manufacturers have filed generics. Analysts quoted in the Chinese press expect generics to price at roughly a third of the originator. If that plays out, the current range is a waypoint rather than a floor.
6. What It Costs
Reported for completeness, with sources. Yuan figures are per box of four weekly doses.
| Drug | Price per box (4 doses) |
|---|---|
| Tirzepatide (穆峰达) — lowest to higher dose | ¥324 – ¥937 |
| Semaglutide (诺和盈) — lowest to maintenance dose | ¥231 – ¥1,284 |
| Mazdutide (信尔美) — 2mg, 2 pens | ¥430 (online, subsidised lower) |
For reference, US list prices in 2026 run at roughly $1,271 a month for tirzepatide and $1,350–$1,640 for semaglutide, before manufacturer discount programmes that can bring semaglutide to $199–$349. How much that difference matters is a judgement for you rather than a claim from us.
7. The Constraints Worth Knowing
These are prescription medicines. Not sold over the counter. A Chinese physician assesses you, and GLP-1 medicines need titration over weeks with monitoring.
Chinese insurance does not cover them for weight loss. Tirzepatide's reimbursement listing, effective 1 January 2026, covers type 2 diabetes. Weight-management use is self-paid at the same reduced price.
Importing them into your own country may be restricted. Personal importation of prescription medicines is limited or prohibited in many jurisdictions. That is a question for your own country's rules, not a medical one, and it is the most common misunderstanding about buying medicine abroad.
Supply continuity is the real problem. This is ongoing treatment. A single trip or shipment does not solve month twelve.
8. What We Can and Cannot Do
China Hospitals Guide matches international patients to Chinese hospitals. Here that means we can help arrange a consultation with an endocrinology or bariatric department, obtain a treatment plan and a written quote, and coordinate travel and interpretation.
We do not sell, ship, prescribe or import medicines, and we cannot obtain a prescription without a physician assessing you. We cannot advise on your own country's import rules. If your interest is surgery rather than medication, our weight-loss surgery guide covers how sleeve and bypass operations are chosen.
9. Frequently Asked Questions
How effective are Chinese weight-loss drugs?
In Phase III trials reported to date, BGM0504 produced 19.2% mean weight loss at 52 weeks at 15mg, and olatorepatid 19.3% at week 48. For context, tirzepatide's pivotal SURMOUNT-1 trial reported 22.5% at 72 weeks. These are separate trials with different populations and durations, not head-to-head comparisons, so the figures should not be divided to produce a percentage-of-equivalence.
What is mazdutide and is it approved?
A dual GCG and GLP-1 receptor agonist from Innovent Biologics, sold in China as 信尔美. NMPA approved it on 27 June 2025 for long-term weight management, and Chinese industry coverage describes it as the first GCG/GLP-1 dual agonist approved anywhere for that indication.
How well tolerated are these drugs?
Across the GLP-1 class the dominant side effects are gastrointestinal and typically transient. In the BGM0504 Phase III trial, discontinuation for adverse events ran at 0.7% to 1.7% across dose groups, with reactions described as mild to moderate and no new safety signals. Tolerability is more directly comparable between drugs than weight-loss percentages, because it is reported consistently across trials.
Do I need a prescription for weight-loss drugs in China?
Yes. They are prescription medicines and not sold over the counter. A Chinese physician assesses you first, and GLP-1 medicines require dose titration over weeks with monitoring. Chinese medical insurance does not cover them for weight loss.
What do weight-loss drugs cost in China?
After the January 2026 price adjustment, a box of four weekly tirzepatide pens costs about ¥324 to ¥937 depending on dose, and semaglutide ¥231 to ¥1,284. Weight-loss use is self-paid. We report these figures for information; whether they matter to you is your own comparison to make.
Ask About Obesity Treatment in China
If you are considering treatment in China for obesity or a related metabolic condition, send us your height, weight, relevant blood results and current medication. We will tell you which hospital departments handle it, what a consultation and a written quote would cover, and what the practical timeline looks like. No obligation, 100% confidential, we reply within 24 hours.
- 📧 Email: contact@chinahospitalsguide.com
- 💬 WhatsApp: +86 157 6310 7083
- 📨 Telegram: @chinahospitalguide
- 💬 WeChat: chinahospitalguide
- 🌐 Start Free Case Review
Medical Disclaimer This article is general information about clinical trial results and pharmaceutical market developments. It does not constitute medical advice, a prescribing recommendation, or advice on importing medicines. It cannot replace an in-person consultation with a licensed physician. Trial results describe group averages in specific populations and do not predict an individual outcome. Whether any medicine is suitable for you must be assessed by a qualified physician.
Source disclosure Phase III data are from presentations at the 62nd EASD Annual Meeting in Milan as reported by the presenting companies. SURMOUNT-1 figures are from the published tirzepatide trial (72 weeks, n=2,539) as reported in the peer-reviewed literature and the manufacturer's clinical materials. Approval details are from the National Medical Products Administration announcement of 27 June 2025. Chinese prices are from reporting by Yangcheng Evening News and China News Service in January 2026, which agree on the figures cited. US list prices are attributed to GoodRx as reported in April 2026. China Hospitals Guide is an independent hospital-matching platform, does not sell or ship medicines, and does not accept commissions from hospitals.
